Actively Recruiting
Prediction of Reverse Remodeling and Outcome in Patients With Severe Secondary Mitral Valve Regurgitation Undergoing Transcatheter Edge-to-edge Mitral Valve Repair
Led by Insel Gruppe AG, University Hospital Bern · Updated on 2024-10-18
300
Participants Needed
1
Research Sites
230 weeks
Total Duration
On this page
Sponsors
I
Insel Gruppe AG, University Hospital Bern
Lead Sponsor
U
University Hospital, Basel, Switzerland
Collaborating Sponsor
AI-Summary
What this Trial Is About
The investigators' hypothesis is that CMR tissue characterization and myocardial function analysis acquired by CMR feature tracking technique predict reverse remodeling in patients with severe secondary mitral regurgitation (MR) undergoing transcatheter mitral edge-to-edge repair.
CONDITIONS
Official Title
Prediction of Reverse Remodeling and Outcome in Patients With Severe Secondary Mitral Valve Regurgitation Undergoing Transcatheter Edge-to-edge Mitral Valve Repair
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with severe secondary mitral regurgitation defined by regurgitant volume 230 mL/beat or effective regurgitant orifice 20 mm
- Symptomatic patients with New York Heart Association Class II or higher
- Left ventricular ejection fraction between 15% and 50%
- Receiving optimal standard heart failure care as determined by investigator
- Not eligible for mitral surgery intervention according to Heart Team
- Able to understand study requirements and provide written consent
You will not qualify if you...
- Younger than 18 years old
- Pregnant or breastfeeding
- Severe kidney function impairment with GFR less than 15 ml/min
- Untreated severe other valve diseases such as severe tricuspid regurgitation or aortic stenosis
- Medical conditions or serious illnesses that reduce ability to comply with study and follow-up
- Contraindications to CMR including certain metallic implants, pacemakers, defibrillators, neurostimulators, aneurysm clips, cochlear implants, infusion pumps, or severe claustrophobia
- Clinically unstable or stage D congestive heart failure or unable to lie flat for 60 minutes
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Cardiology, University Hospital Bern, Inselspital, Bern
Bern, Switzerland, 3010
Actively Recruiting
Research Team
C
Christoph MD Gräni, PHD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here